undamentalytics Newsletter
Sign in

Auerbach Alan H: insider trades

Chief executive at Puma Biotechnology, Inc. No open-market purchases and 20 sales not made under a pre-set plan, reported from January 4, 2019 to January 5, 2023.

What happened after Auerbach Alan H’s sales?

After their sales, the shares moved −65.4% against the index over 12 months on average (a negative figure means selling was the right call); 94% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

Trade by trade

MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 0 — — — — — — Not enough years
Purchases, 6 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the trade 0 — — — — — — Not enough years
Sales, 3 months after the report 17 −32.9% −29.4% 88% 3 — — Not enough years
Sales, 12 months after the report 17 −65.4% −67.8% 94% 3 — — Not enough years
Sales, 12 months after the trade 17 −68.5% −70.2% 94% 3 — — Not enough years

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Puma Biotechnology, Inc. PBYI President and CEO020January 4, 2019January 5, 2023

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
January 5, 2023January 3, 2023 PBYI Sale $113,867 not yetnot yetnot yet
July 7, 2022July 5, 2022 PBYI Sale $68,748 not yetnot yetnot yet
January 5, 2022January 3, 2022 PBYI Sale $72,971 not yetnot yetnot yet
November 3, 2021November 2, 2021 PBYI Sale $10,106 −58.6%−39.4%−47.1%
October 6, 2021October 4, 2021 PBYI Sale $11,427 −62.8%−46.0%−49.6%
September 3, 2021September 2, 2021 PBYI Sale $13,406 −61.3%−55.2%−53.3%
August 3, 2021August 2, 2021 PBYI Sale $13,283 −16.1%−48.0%−56.1%
July 6, 2021July 2, 2021 PBYI Sale $47,135 −24.8%−56.5%−59.2%
June 4, 2021June 2, 2021 PBYI Sale $18,870 −43.6%−78.1%−81.4%
May 5, 2021May 3, 2021 PBYI Sale $15,840 −33.5%−76.9%−77.7%
April 6, 2021April 5, 2021 PBYI Sale $15,523 −19.0%−77.1%−83.0%
March 4, 2021March 2, 2021 PBYI Sale $12,553 −6.7%−91.0%−89.1%
February 4, 2021February 2, 2021 PBYI Sale $14,933 −29.4%−97.5%−99.0%
January 6, 2021January 4, 2021 PBYI Sale $186,362 −25.2%−100.3%−100.4%
July 6, 2020July 2, 2020 PBYI Sale $27,791 −15.1%−64.1%−57.2%
January 3, 2020January 2, 2020 PBYI Sale $50,471 +13.1%+15.3%+4.5%
May 6, 2019May 2, 2019 PBYI Sale $15,445 −70.4%−68.0%−70.2%
April 3, 2019April 2, 2019 PBYI Sale $17,573 −68.9%−67.8%−67.2%
March 22, 2019March 4, 2019 PBYI Sale $19,156 −72.3%−67.0%−83.4%
January 4, 2019January 3, 2019 PBYI Sale $91,444 +34.6%−94.4%−94.3%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Auerbach Alan H traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.